Entropy Neurodynamics Limited
ENP.ASXHealth Care
Research and development of pharmaceuticals and biotechnology
Market Data
$0.032
+0.0%$50.6M
-100000.0x
$-0.003
0.00%
-0.1%
Latest Earnings
Appendix 4D and Half Year Report for period 31 Dec 2025
27 February 2026
Entropy Neurodynamics (formerly Tryptamine Therapeutics) reported a H1 2025 loss of $3.4M, down 14.8% year-on-year, with revenue up 999% to $48.5k from interest income. The company achieved major clinical milestones including first patient dosing in its world-first Binge Eating Disorder trial using TRP-8803, secured $6.1M in new funding and $2.6M in non-dilutive R&D loans, and signed a landmark biomarker collaboration with Imperial College London to develop an EEG-based precision psychiatry platform. Key points: First patient successfully dosed in world-first BED trial using TRP-8803 IV-infused psilocin in October 2025; second dose administered 15 December 2025 with full psychedelic response achieved; Two patients now enrolled in BED trial with strong initial interest and recruitment advancing; partnership with Butterfly Foundation supporting patient engagement; Landmark exclusive biomarker development agreement with Imperial College London (Professors Carhart-Harris and Mediano) to validate real-time EEG-based brain entropy biomarker for precision psychiatry and outcome prediction
Recent Announcements
Appendix 4D and Half Year Report for period 31 Dec 2025
Entropy Neurodynamics (formerly Tryptamine Therapeutics) reported a H1 2025 loss of $3.4M, down 14.8% year-on-year, with revenue up 999% to $48.5k from interest income. The company achieved major clinical milestones including first patient dosing in its world-first Binge Eating Disorder trial using TRP-8803, secured $6.1M in new funding and $2.6M in non-dilutive R&D loans, and signed a landmark biomarker collaboration with Imperial College London to develop an EEG-based precision psychiatry platform. Key points: First patient successfully dosed in world-first BED trial using TRP-8803 IV-infused psilocin in October 2025; second dose administered 15 December 2025 with full psychedelic response achieved; Two patients now enrolled in BED trial with strong initial interest and recruitment advancing; partnership with Butterfly Foundation supporting patient engagement; Landmark exclusive biomarker development agreement with Imperial College London (Professors Carhart-Harris and Mediano) to validate real-time EEG-based brain entropy biomarker for precision psychiatry and outcome prediction
Get real-time alerts for ENP
Receive AI-powered earnings summaries and instant notifications when Entropy Neurodynamics Limited releases results.
Register Free